Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q15147

UPID:
PLCB4_HUMAN

ALTERNATIVE NAMES:
Phosphoinositide phospholipase C-beta-4; Phospholipase C-beta-4

ALTERNATIVE UPACC:
Q15147; B7ZLK6; E2QRH8; Q17R56; Q5JYS8; Q5JYS9; Q5JYT0; Q5JYT3; Q5JYT4; Q9BQW5; Q9BQW6; Q9BQW8; Q9UJQ2

BACKGROUND:
The enzyme 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4, known alternatively as Phosphoinositide phospholipase C-beta-4, is integral to generating key signaling molecules, DAG and IP3, within the cell. Its function is especially critical in the context of retina signal transduction.

THERAPEUTIC SIGNIFICANCE:
Given its link to Auriculocondylar syndrome 2, characterized by distinct craniofacial anomalies, the study of Phospholipase C-beta-4 offers a promising avenue for developing novel treatments. Understanding the role of this protein could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.